QUEBEC CITY, June 22, 2016 /CNW Telbec/ - Opsens Inc.
("Opsens" or the "Company") (TSXV:OPS) (OTCQX:OPSSF) today
announced receipt of Health Canada approval to sell the OptoWire II
in Canada. The OptoWire II is an
optical guidewire developed to measure Fractional Flow Reserve
("FFR"). FFR measurement is used for the diagnostic
of the severity of coronary stenosis to guide treatment in patients
with coronary artery disease.
"Opsens is pleased to offer its improved optical guidewire to
Canadian cardiologists, where the Company already has multiple
regular customers," said Louis
Laflamme, President and CEO of Opsens. "The OptoWire II is
now authorized for sale in all our targeted markets: U.S.,
Europe, Japan and Canada, which together represent 85% of the
FFR worldwide market," he concluded.
In order to provide cardiologists with the most effective
products to measure FFR, Opsens has developed the OptoWire II, an
improved version of the original OptoWire, which has a hydrophilic
coating that further enhances the performances of the guidewire,
such as when used in highly calcified and tortuous vessels.
The interventional cardiology community has provided a warm and
enthusiastic welcome to Opsens' FFR products, prompting the Company
to put in place the resources to grow strongly. Opsens has
assembled a team with experience and expertise in the sale of FFR
products. In addition, Opsens has completed its move to a new
state-of-the-art facility, which will allow the Company to increase
production and meet the growing demand for its FFR products.
Opsens aims to become a key player in the guidewire FFR market
with the OptoWire, a nitinol-based optical guidewire. The OptoWire
provides intra-coronary blood pressure measurements with unique,
patented optical pressure guidewire technologies. It is immune to
adverse effects related to blood contact, and allows easy and
reliable connectivity that leads to reliable FFR measurements in
extended conditions of usage. The OptoWire is also designed to
provide cardiologists with a guidewire that provides optimal
performance to navigate coronary arteries and cross blockages with
ease and safety. Based on industry sources, the FFR market
represented more than US$300 million
in sales in 2014 and is expected to reach US$1 billion in the medium-term.
About Opsens Inc. (www.opsens.com or
www.opsensmedical.com)
Opsens focuses mainly on the measure of FFR in interventional
cardiology. Opsens offers an advanced optical-based pressure
guidewire (OptoWire) that aims at improving the clinical outcome of
patients with coronary artery disease. Opsens is also involved in
industrial activities. The Company develops, manufactures and
installs innovative fibre optic sensing solutions for critical
applications such as the monitoring of oil wells and other
demanding industrial applications.
Forward-looking statements contained in this press release
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance and achievements of
Opsens to be materially different from any future results,
performance or achievements expressed or implied by the said
forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE OPSENS INC.